Early pregnancy exposure to selective serotonin reuptake inhibitors, risks of major structural malformations, and hypothesized teratogenic mechanisms

Bibliography

• Sundstrom IM, Bixo M, Bjorn I, et al. Prevalence of psychiatric disorders in gynaecologic outpatients. Am J Obstet Gynecol 2001;184:8-13
   PubMed Web of Science ®Google Scholar
• Andersson L, Sundtrom-Poroma I, Bixo M, et al. Point prevalence of psychiatric disorders during the second trimester of pregnancy: a population-based study. Am J Obstet Gynecol 2003;189:148-54
   PubMed Web of Science ®Google Scholar
• Qiao YX, Wang J, Li J, et al. The prevalence and related risk factors of anxiety and depressive symptoms among Chinese pregnant women in Shanghai. Aust N Z J Obstet Gynaecol 2009;49:185-90
   PubMed Web of Science ®Google Scholar
• Halbtreich U. Prevalence of mood symptoms and depression during pregnancy: implications for clinical practice and research. CNS Spectr 2004;9:177-84
   PubMed Web of Science ®Google Scholar
• Lara AM, Le HN, Letechipia G, et al. Prenatal depression in latinas in the U.S. and Mexico. Matern Child Health J 2009;13:567-76
   PubMed Web of Science ®Google Scholar
• Dayan J, Creveuil C, Marks MN, et al. Prenatal depression, prenatal anxiety, and spontaneous preterm birth: a prospective cohort study among women with early and regular care. Psychosom Med 2006;68:938-46
   PubMed Web of Science ®Google Scholar
• Andersson L, Sundrtrom-Poroma I, Wulff M, et al. Implication of antenatal depression and anxiety for obstetric outcome. Obstet Gynecol 2004;104:467-76
   PubMed Web of Science ®Google Scholar
• Brand SR, Brennan PA. Impact of antenatal and postpartum maternal mental illness: how are the children? Clin Obstet Gynecol 2009;52:441-55
   PubMed Web of Science ®Google Scholar
• Skouteris HM, Wertheim EH, Rallis S, et al. Depression and anxiety through pregnancy and the early postpartum: an examination of prospective relationships. J Affect Disord 2009;113:303-8
   PubMed Web of Science ®Google Scholar
• Sutter-Dallay AL, Giaconne-Marchesche V, Glatigny-Dallay E, et al. Women with anxiety disorders during pregnancy are at increased risk of intense postnatal depressive symptoms: a prospective survey of the MATQUID cohort. Eur Psychiatry 2004;19:459-63
   PubMed Web of Science ®Google Scholar
• O’Connor TG, Heron J, Glover V, et al. ALSPAC STUDY TEAM. Antenatal anxiety predicts child behavioral/emotional problems independently of postnatal depression. J Am Acad Child Adolesc Psychiatry 2002;41:1470-7
   PubMed Web of Science ®Google Scholar
• Gentile S. Drug treatment for mood disorders in pregnancy. Curr Opin Psychiatry 2011;24:34-40
   PubMed Web of Science ®Google Scholar
• Petersen I, Gilbert RE, Evans SJ, et al. Pregnancy as a major determinant for discontinuation of antidepressants: an analysis of data from The Health Improvement Network. J Clin Psychiatry 2011;72:979-85
   PubMed Web of Science ®Google Scholar
• Goodman JH. Women’s attitude, preferences, and perceived barriers to treatment for perinatal depression. Birth 2009;36:60-9
   PubMed Web of Science ®Google Scholar
• Cook CA, Flick LH, Homan SM, et al. Psychiatric disorders and treatment of low-income pregnant women. J Womens Health 2010;19:1251-62
   PubMed Web of Science ®Google Scholar
• Gentile S. The safety of newer antidepressants in pregnancy and breastfeeding. Drug Saf 2005;28:137-52
   PubMed Web of Science ®Google Scholar
• Mulder EJH, Ververs FFT, de Heus R, et al. Selective serotonin reuptake inhibitors affect neurobehavioral development in the human fetus. Neuropsychopharmacology 2011;36:1961-71
   PubMed Web of Science ®Google Scholar
• Casper RC, Fleisher BE, Lee-Ancajas JC, et al. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatr 2003;4:402-8
   Web of Science ®Google Scholar
• Gentile S. On categorizing gestational, birth, and neonatal complications following late in utero exposure to antidepressants. The prenatal antidepressant exposure syndrome. CNS Spectr 2010;15:167-85
   PubMed Web of Science ®Google Scholar
• FDA Public Health Advisory. Paroxetine. Available from: http://69.20.19.211/cder/drug/advisory/paroxetine200512.htm [Last accessed on 10 May 2008]
   Google Scholar
• Gentile S. Selective serotonin reuptake inhibitor exposure during early pregnancy and the risk of birth defects. Acta Psychiatr Scand 2011;123:266-75
   PubMed Web of Science ®Google Scholar
• Gentile S, Bellantuono C. SSRI-exposure during early pregnancy and the risk of fetal major malformations. Focus on paroxetine. J Clin Psychiatry 2009;70:414-22
   PubMed Web of Science ®Google Scholar
• Bellantuono C, Migliarese G, Gentile S. Serotonin reuptake inhibitors in pregnancy and the risk of major malformations: a systematic review. Hum Psychopharmacol 2007;22:121-8
   PubMed Web of Science ®Google Scholar
• Einarson A. Publishing statistically significant results with questionable clinical importance: focus on antidepressant use during pregnancy. J Clin Psychiatry 2012;73:1443-5
   PubMed Web of Science ®Google Scholar
• Gentile S. Managing antidepressant treatment in pregnancy and puerperium. Careful with that axe, Eugene. Expert Opin Drug Saf 2015;1-4. [Epub ahead of print]
   PubMedGoogle Scholar
• Diav-Citrin O, Schechtman S, Weinbaum D, et al. Pregnancy outcome after gestational exposure to paroxetine: a prospective controlled cohort study [Abstract]. Teratology 2000;65:S298
   Google Scholar
• Diav-Citrin O, Schechtman S, Weinbaum D, et al. Paroxetine and fluoxetine in pregnancy: a multicenter, prospective, controlled study [Abstract]. Repr Toxicol 2005;20:S459
   Google Scholar
• Diav-Citrin O, Schechtman S, Weinbaum D, et al. Paroxetine and fluoxetine in pregnancy: a multicenter, prospective, controlled study. Br J Clin Pharmacol 2008;66:695-705
   PubMed Web of Science ®Google Scholar
• Furu K, Kieler H, Haglund B, et al. Selective serotonin reuptake inhibitors and venlafaxine in early pregnancy and risk of birth defects: population based cohort study and sibling design. BMJ 2015;350:h1798
   PubMed Web of Science ®Google Scholar
• Bakker K, Kerstjens-Frederikse WS, Buys CHCM, et al. First-trimester use of paroxetine and congenital heart defects: a population-based case-control study. Birth Def Res Part A Clin Mol Teratol 2010;88:94-100
   PubMed Web of Science ®Google Scholar
• Bakker MK, De Walle HEK, Wilffert B, et al. Fluoxetine and infantile hypertrophic pylorus stenosis: a signal from a birth defects-drug exposure surveillance study. Pharmacoepidemiol Drug Saf 2010;19:808-13
   PubMed Web of Science ®Google Scholar
• Louik C, Lin AE, Werler MM, et al. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. New Engl J Med 2007;356:2675-83
   PubMed Web of Science ®Google Scholar
• Alwan S, Reefhuis J, Rasmussen SA, et al. Maternal use of selective serotonin reuptake inhibitors and risk for birth defects [Abstract]. Clin Mol Teratol 2005;7:291
   Google Scholar
• Alwan S, Reefhuis J, Rasmussen SA, et al. National Birth Defects Prevention Study. Use of selective serotonin reuptake inhibitors and risk of birth defects. New Engl J Med 2007;356:2684-92
   PubMed Web of Science ®Google Scholar
• Malm H, Artama M, Gissler M, et al. Risks associated with the use of selective serotonin reuptake inhibitors (SSRIs) during pregnancy-New data based on national registers. Reprod Toxicol 2010;30:221
   Google Scholar
• Christianson A, Howson CP, Modell B. Executive summary. Global report on birth defects. The hidden tool of dying and disabled children. Available from: http://www.neonatology.org/pdf/MODBDExecutiveSummary.pdf [Last accessed on 6 June 2015]
   Google Scholar
• Center for Disease Control. Birth Defects. Available from: http://www.cdc.gov/ncbddd/birthdefects/data.html [Last accessed on 6 June 2015]
   Google Scholar
• van der Linde D, Konings EEM, Maarten A, et al. Birth prevalence of congenital heart disease worldwide. : A Systematic review and meta-analysis. Am Coll Cardiol 2011;58:2241-7
   PubMed Web of Science ®Google Scholar
• The BMJ. Quantifying disease in populations. Available from: http://www.bmj.com/about-bmj/resources-readers/publications/epidemiology-uninitiated/2-quantifying-disease-populations [Last accessed on 7 June 2015]
   Google Scholar
• Reis M, Källén B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med 2010;40:1723-33
   PubMed Web of Science ®Google Scholar
• Källén B, Otterblad-Olausson P. Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Def Res A Clin Mol Teratol 2007;79:301-8
   PubMed Web of Science ®Google Scholar
• Källén B, Otterblad-Olausson P. Antidepressant drugs during pregnancy and infant congenital heart defect [Letter]. Repr Toxicol 2006;21:221-2
   PubMed Web of Science ®Google Scholar
• Wogelius P, Nørgaard M, Gislum M, et al. Maternal use of serotonin reuptake inhibitors and risk of congenital malformations. Epidemiology 2006;17:701-4
   PubMed Web of Science ®Google Scholar
• Wogelius P, Nørgaard M, Munk EM, et al. Maternal use of serotonin reuptake inhibitors and risk of adverse pregnancy outcomes [Abstract]. Pharmacoepidemiolol Drug Saf 2005;14:S72-3
   Google Scholar
• Pedersen LH, Henriksen TB, Vestergaard M, et al. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: a population based cohort study. Br Med J 2009;339:b3569
   PubMed Web of Science ®Google Scholar
• Kornum JB, Nielsen RB, Pedersen L, et al. Use of selective serotonin reuptake inhibitors during early pregnancy and the risk of congenital malformations: updated analysis. Clin Epidemiol 2010;2:29-36
   PubMedGoogle Scholar
• Jimenez-Solem E, Traerup Andersen T, Petersen M, et al. Exposure to selective serotonin reuptake inhibitors and the risk of congenital malformations: a nationwide cohort study. BMJ Open 2012;2:e001148
   PubMed Web of Science ®Google Scholar
• Knudsen TM, Hansen AV, Game E, Nybo Andersen AM. Increased risk of severe congenital heart defects in offspring exposed to selective serotonin reuptake inhibitors in early pregnancy - an epidemiological study using validated EUROCAT data. BMC Pregn Childbirth 2014;14:333
   PubMed Web of Science ®Google Scholar
• Munch TN, Hee Rasmussen ML, Wohlfahrt J, et al. Risk factors for congenital hydrocephalus: a nationwide, register-based, cohort study. J Neurol Neurosurg Psychiatry 2014;85:1253-9
   PubMed Web of Science ®Google Scholar
• de Jonge L, Priscilla A, van der Woude Z, et al. Identifying associations between maternal medication use and birth defects using a case-population approach: an exploratory study on signal detection. Drug Saf 2013;36:1069-78
   PubMed Web of Science ®Google Scholar
• Bakker MK, De Walle HEK, Wilffert B, de Jong-Van Den Berg LTW. Fluoxetine and infantile hypertrophic pylorus stenosis: a signal from a birth defects–drug exposure surveillance study. Pharmacoepidemiol Drug Saf 2010;18(8):808-13
   Web of Science ®Google Scholar
• Ban L, Gibson JE, West J, et al. Maternal depression, antidepressant prescriptions, and congenital anomaly risk in offspring: a population-based cohort study. BJOG 2014;121:1471-81
   PubMed Web of Science ®Google Scholar
• Merlob P, Birk E, Sirota L, et al. Are serotonin reuptake inhibitors cardiac teratogens? Echocardiographic screening of newborns with persistent heart murmur. Birth Def Res Part A Clin Mol Teratol 2009;85:837-41
   PubMed Web of Science ®Google Scholar
• Oberlander TF, Warburton W, Misri S, et al. Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. Birth Def Res Part B 2008;83:68-76
   PubMed Web of Science ®Google Scholar
• Bèrard A, Ramos E, Rey E, et al. First trimester exposure to paroxetine and risk of cardiac malformations in the infants: the importance of dosage. Birth Defects Res Part B Dev Reprod Toxicol 2007;80:18-27
   PubMed Web of Science ®Google Scholar
• Bérard A, Zhao JP, Sheehy O. Sertraline use during pregnancy and the risk of major malformations. Am J Obstet Gynecol 2015. [Epub ahead of print]
   Google Scholar
• GlaxoSmithKline. Epidemiology study EPIP08. Preliminary Report on Bupropion in Pregnancy and the Occurrence of Cardiovascular and major structural malformations. Available from: http://ctr.gsk.co.uk/summary/paroxetine/epip083.pdf [Last accessed on 15 August 2008]
   Google Scholar
• GlaxoSmithKline. EPIP083. Updated preliminary report. Available from: http://ctr.gsk.co.uk/summary/paroxetine/epip083part2.pdf [Last accessed on 15 August 2008]
   Google Scholar
• GlaxoSmithKline. EPI40404. Follow-up to EPIPO83. Available from: http://ctr.gsk.co.uk/summary/paroxetine/epi40404.pdf [Last accessed on 15 August 2008]
   Google Scholar
• Cole JA, Ephross SA, Cosmatos IS, et al. Paroxetine in the first trimester and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf 2007;16:1075-85
   PubMed Web of Science ®Google Scholar
• Knickmeye RC, Meltzer-Brody S, Sandra Woolson S, et al. Rate of Chiari I malformation in children of mothers with depression with and without prenatal SSRI exposure. Neuropsychopharmacology 2014;39:2611-21
   PubMed Web of Science ®Google Scholar
• Yazdy MM, Mitchel AA, Louik C, Werler MM. Use of selective serotonin-reuptake inhibitors during pregnancy and the risk of clubfoot. Epidemiology 2014;25:859-65
   PubMed Web of Science ®Google Scholar
• Louik C, Lin AE, Werler MW, et al. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 2007;356:2675-83
   PubMed Web of Science ®Google Scholar
• Velligan DI, Weiden PJ, Sajatovic M, et al. Expert consensus panel on adherence problems in serious and persistent mental illness. J Clin Psychiatry 2009;70(suppl 4):1-46
   PubMed Web of Science ®Google Scholar
• Hansen RA, Dusetzina SB, Dominik RC, et al. Prescription refill records as a screening tool to identify antidepressant non-adherence. Pharmacoepidemiol Drug Saf 2010;19:33-7
   PubMed Web of Science ®Google Scholar
• Swanson SA, Hernandez-Diaz S, Palmsten K, et al. Methodological considerations in assessing the effectiveness of antidepressant medication continuation during pregnancy using administrative data. Pharmacoepidemiol Drug Saf 2015. [Epub ahead of print]
   PubMedGoogle Scholar
• Sánchez C, Hyttel J. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Mol Neurobiol 1999;19:467-9
   PubMed Web of Science ®Google Scholar
• Trontell A. Expecting the unexpected -Drug Safety, Pharmacovigilance, and the Prepared Mind. N Engl J Med 2004;351:1385-7
   Google Scholar
• Gary SchoenwolfX. Larsen’s human embryology. 5th edition. Churchill Livingstone, Inc; UK: 2015
   Google Scholar
• Bonnin A, Levitt P. Fetal, maternal, and placental sources of serotonin and new implications for developmental programming of the brain. Neuroscience 2011;197:1-7
   PubMed Web of Science ®Google Scholar
• Olivier JDA, Åkerud H, Skalkidou A, et al. The effects of antenatal depression and antidepressant treatment on placental gene expression. Front Cell Neurosci 2015;8:1-17
   Web of Science ®Google Scholar
• Kusakawa S, Yamauchi J, Miyamoto Y, et al. Estimation of embryotoxic effect of fluoxetine using embryonic stem cell differentiation system. Life Sci 2008;83:871-7
   PubMed Web of Science ®Google Scholar
• Noorlander CW, Ververs FF, Nikkels PG, et al. Modulation of serotonin transporter function during fetal development causes dilated heart cardiomyopathy and lifelong behavioral abnormalities. PLoS One 2008;3:e2782
   PubMed Web of Science ®Google Scholar
• Pavone LM, Spina A, Rea S, et al. Serotonin transporter gene deficiency is associated with sudden death of newborn mice through activation of TGF-β1 signalling. J Molec Cell Cardiology 2009;47:691-7
   PubMed Web of Science ®Google Scholar
• Levin M, Buznikov GA, Lauder JM. Of minds and embryos: left-right asymmetry and the serotonergic controls of pre-neural morphogenesis. Dev Neurosci 2006;28:171-85
   PubMed Web of Science ®Google Scholar
• Moiseiwitsch JR. The role of serotonin and neurotransmitters during craniofacial development. Crit Rev Oral Biol Med 2000;11(2):230-9
   PubMedGoogle Scholar
• Altura BM, Malaviya D, Reich CF, Orkin LR. Effects of vasoactive agents on isolated human umbilical arteries and vein. Am J Physiol 1972;222:345-55
   PubMed Web of Science ®Google Scholar
• Dalmizrak O, Kulaksiz-Erkmen G, Ozer N. The inhibition characteristics of human placental glutathione S-transferase- π by tricyclic antidepressants: amitriptyline and clomipramine. Mol Cell Biochem 2011;355:223-31
   PubMed Web of Science ®Google Scholar
• Vial T, Bernard N, Carlier P, et al. Paroxetine and congenital malformations: a prospective comparative study [abstract n. 228). Fund Clin Pharmacol 2006;20:223
   Google Scholar
• Wichman CL, Moore KM, Lang TR, et al. Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy. Mayo Clin Proc 2009;84(1):23-7
   PubMed Web of Science ®Google Scholar
• Einarson A, Choi J, Einarson TR, Koren G. Incidence of major malformations in infants following antidepressant exposure in pregnancy: results of a large prospective cohort study. Can J Psychiatry 2009;54(4):242-6
   PubMed Web of Science ®Google Scholar
• Jimenez-Solem E, Andersen JT, Petersen M, et al. Exposure to selective serotonin reuptake inhibitors and the risk of congenital malformations: a nationwide cohort study. BMJ Open 2012;2:e001148
   PubMed Web of Science ®Google Scholar
• Nordeng H, van Gelder MMHJ, Spigset O, et al. Pregnancy outcome after exposure to antidepressants and the role of maternal depression. Results from the Norwegian Mother and Child Cohort Study. J Clin Psychopharmacol 2012;32:186-94
   PubMed Web of Science ®Google Scholar
• Margulis AV, Abou-Ali A, Strazzeri MM, et al. Use of selective serotonin reuptake inhibitors in pregnancy and cardiac malformations: a propensity-score matched cohort in CPRD. Pharmacoepidemiol Drug Saf 2013;22(9):942-51
   PubMed Web of Science ®Google Scholar
• Huybrechts KF, Palmsten K, Avorn J, et al. Antidepressant use in pregnancy and the risk of cardiac defects. N Engl J Med 2014;370:2397-407
   PubMed Web of Science ®Google Scholar
• Einarson A, Pistelli A, DeSantis M, et al. Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy. Am J Psychiatry 2008;165(6):749-52
   PubMed Web of Science ®Google Scholar
• Alpert BS, Cook DH, Varghese PJ, et al. Spontaneous closure of small ventricular septal defects: ten-year follow-up. Pediatrics 1979;63(2):204-6
   PubMed Web of Science ®Google Scholar
• Chiu WH, Hsiung MC, Chen RC, et al. Prenatal ultrasonography and Doppler sonography for the clinical investigation of isolated ventricular septal defects in a late second-trimester population. Eur J Med Res 2014;19:3
   PubMed Web of Science ®Google Scholar
• Sit DK, Perel JM, Wisner KL. Changes in antidepressant metabolism and dosing across pregnancy and early postpartum. J Clin Psychiatry 2008;61(4):652-8
   Google Scholar
• Hostetter A, Stowe ZN, Strader JRJr, et al. Dose of selective serotonin uptake inhibitors across pregnancy: clinical implications. Depress Anx 2000;11:51-7
   PubMed Web of Science ®Google Scholar
• Ververs FFT, Voorbij HAM, Zwarts P, et al. Effect of cytochrome P4502D6 genotype on maternal paroxetine plasma concentrations during pregnancy. Clin Pharmacokinet 2009;48(10):677-83
   PubMed Web of Science ®Google Scholar
• DeVane CL, Stowe ZN, Donovan JL, et al. Therapeutic drug monitoring of psychoactive drugs during pregnancy in the genomic era: challenges and opportunities. J Psychopharmacol 2006;20(4 Suppl):54-9
   PubMedGoogle Scholar
• NHS choice. Congenital heart disease. Prevention. Available from: http://www.nhs.uk/Conditions/Congenital-heart-disease/Pages/Prevention.aspx [Last accessed on 20 February 2013]
   Google Scholar
• Feng Y, Wang S, Chen R, et al. Maternal folic acid supplementation and the risk of congenital heart defects in offspring: a meta-analysis of epidemiological observational studies. Sci Rep 2015;5:8506 10.1038/srep08506
   Web of Science ®Google Scholar
• Li X, Li S, Mu D, et al. The association between periconceptional folic acid supplementation and congenital heart defects: a case-control study in China. Prev Med 2013;56(6):385-9
   PubMed Web of Science ®Google Scholar